Cyber breaches and insider threats, including malicious insiders stealing, manipulating or destroying data, are the fastest-growing risks and are driving investment in Forensic Data Analytics (FDA), a report said.
Lunatus Marketing and Consulting, a leading Middle East based firm focused on linking international health care companies with the region’s healthcare professionals, has launched ‘Cefaly,’ the first FDA-approved anti-migraine
A controversial drug to treat low sexual desire in women won approval from the US Food and Drug Administration on Tuesday, but with a warning about potentially dangerous side effects.
The FDA has twice rejected the drug, flibanser
An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the US Food and Drug Administration.
Developed by Auxilium Pharmaceuticals and Vivus, the drug,
The US Food and Drug Administration approved GlaxoSmithKline's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.
Tanzeum will carry a warning on its label that tumors of the thy
Celgene Corporation said the US Food and Drug Administration (FDA) has approved Otezla (apremilast), the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthrit
Some US doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration.
India supplies about 40 percent of gener
The US Food and Drug Administration has proposed banning artificial trans fats in processed food ranging from cookies to frozen pizza, citing the risk of heart disease.
Partially hydrogenated oils, the primary dietary source of th
US health regulators expanded the approval of Roche Holding's breast cancer drug Perjeta and will now allow its use to help shrink tumors prior to surgery, the Food and Drug Administration said on Monday.
The decision followed
US health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate the hepatitis B virus in patients previously infected with the disease.
The warnings affect GlaxoSmithKline